WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting

Animal Health

Open PDF
  • Wilson Sonsini Represents a Range of Clients in the Animal Health Sector

    We represent a number of different animal health breeds—from companies focused on companion animal well-being to organizations focused on wildlife conservation. Our clients include early-stage start-ups, as well as established late-stage companies, several of which operate at the intersection of technology and veterinary medicine. We also represent venture capital firms and other investors that support the growth and development of animal health entities.

  • Our Experience Aligns with Animal Health Client Needs

    Wilson Sonsini’s animal health clients look to us for legal counsel not only because of our legacy of helping companies grow, but also because we have a level of directly relevant and interdisciplinary experience that distinguishes us from competitors, particularly as to corporate, IP, technology transactions, and key regulatory/FDA areas.

  • Wilson Sonsini Offers Growing and Established Animal Health Clients Key Advantages

    There are several advantages we offer to animal health clients: We are a premier provider to venture-backed, private companies, based in part on our strong ties to VC firms, incubators, and financing institutions; our IP practice includes individuals with Ph.D.s and other advanced degrees in veterinary science, biology, chemistry, and other relevant fields; we have a talented FDA/regulatory team; and our West Coast, East Coast, Mountain West, and Texas offices are in or near key U.S. animal health markets.

Representing Animal Health Innovators and the Investors That Support Them

Wilson Sonsini represents companies across the animal health sector, including innovative entrepreneurs, start-ups, and other market entrants, as well as late-stage companies and other established entities. We also represent VC firms and other financial institutions engaged in financing promising animal health ventures and helping companies grow.

On the company side, our experience includes working with clients focused on a wide range of animal health-related areas, from domesticated companion animal care to veterinary facilities. Our animal health team also draws from the firm’s related agtech and foodtech experience, given the intertwined relationship between commercial agriculture, livestock, and the food and nutrition sectors. As the animal health industry continues to grow, so does the firm’s base of clients and the range of areas in which they operate.

Our animal health sector clients focus on important and developing fields, such as:

  • Companion animal care and well-being
  • Comparative oncology
  • DNA testing
  • Gene editing and associated applied technologies 
  • Veterinary pharmaceutical applications
  • Veterinary practice management applications
  • Wildlife conservation and restoration 

Integrated, Multidisciplinary Teams

Just as Wilson Sonsini has always done in the past when innovation and disruptive technologies opened the door to new, fast-growing industries, our firm has formed a multidisciplinary, collaborative team that works closely with health-care-driven scientists, entrepreneurs, and other market entrants who have launched companies focused on developing, commercializing, and marketing animal health products and services. Our team consists of experienced and engaged attorneys from core areas that are key to growing and successful animal health entities, from corporate and IP to regulatory/FDA and technology transactions. Without question, Wilson Sonsini has the experience, insight, and connections to assist animal health companies and investors. At a glance, our most relevant practice areas and services include:

Intellectual Property

  • Patent portfolio management
  • Preparation and prosecution of patent applications
  • Freedom-to-operate analysis
  • IP due diligence
  • Licensing and regulatory submissions
  • IP strategy and development
  • Trademarks, advertising, and promotions

Corporate

  • Corporate governance
  • Venture capital financings
  • Creative corporate structures
  • Capital markets
  • Mergers and acquisitions

Regulatory

  • Compliance counseling on laws, regulations, and industry standards
  • Assessing product development and regulatory approval options
  • Crisis management (responding to audits and other FDA inquiries)
  • Advertising and promotional strategy and review

Technology Transactions

  • Commercial transactions, including collaborations, joint ventures, strategic alliances, and partnering arrangements
  • Manufacturing, supply, and distribution agreements

Why Wilson Sonsini Is the Right Firm for Animal Health and Veterinary Medicine Clients

There are several reasons why we are the right law firm for animal health and veterinary medicine clients. Wilson Sonsini offers comparative advantages to clients across the sector, such as:

  • In addition to having a comprehensive and recognized corporate practice, we are a premier legal services provider to venture-funded technology start-ups with strong ties to VC firms and financing institutions, as well as accelerators and incubators.
  • Many of Wilson Sonsini’s 180-plus patent attorneys and patent agents have Ph.D.s and other advanced degrees in veterinary science, biology, chemistry, biomedical sciences, and other relevant fields. Additionally, more than 130 Wilson Sonsini attorneys and patent agents have been admitted to practice before the USPTO, and our team includes several former USPTO executives and USPTO patent examiners.
  • We have a talented regulatory/FDA team that includes seasoned veterans accustomed to advising clients throughout the FDA application and approval process; counseling companies on product labeling, advertising, and marketing matters; and advising investors on due diligence-related issues.
  • Our West Coast, East Coast, Mountain West, and Texas offices are in or near strategic U.S. animal health markets.

For decades, dating back to the birth of the technology revolution—when Silicon Valley earned its name as base camp for the fearless and daring—Wilson Sonsini has been at the center of innovation. But like our clients, we did not stay idle. Since our inception, we have partnered with companies making novel discoveries and developing the newest technologies. Wilson Sonsini maintains a position of strength that enables it to work effectively, intuitively, and seamlessly with companies and investors across the animal health industry.

Overview

Representing Animal Health Innovators and the Investors That Support Them

Wilson Sonsini represents companies across the animal health sector, including innovative entrepreneurs, start-ups, and other market entrants, as well as late-stage companies and other established entities. We also represent VC firms and other financial institutions engaged in financing promising animal health ventures and helping companies grow.

On the company side, our experience includes working with clients focused on a wide range of animal health-related areas, from domesticated companion animal care to veterinary facilities. Our animal health team also draws from the firm’s related agtech and foodtech experience, given the intertwined relationship between commercial agriculture, livestock, and the food and nutrition sectors. As the animal health industry continues to grow, so does the firm’s base of clients and the range of areas in which they operate.

Our animal health sector clients focus on important and developing fields, such as:

  • Companion animal care and well-being
  • Comparative oncology
  • DNA testing
  • Gene editing and associated applied technologies 
  • Veterinary pharmaceutical applications
  • Veterinary practice management applications
  • Wildlife conservation and restoration 

Integrated, Multidisciplinary Teams

Just as Wilson Sonsini has always done in the past when innovation and disruptive technologies opened the door to new, fast-growing industries, our firm has formed a multidisciplinary, collaborative team that works closely with health-care-driven scientists, entrepreneurs, and other market entrants who have launched companies focused on developing, commercializing, and marketing animal health products and services. Our team consists of experienced and engaged attorneys from core areas that are key to growing and successful animal health entities, from corporate and IP to regulatory/FDA and technology transactions. Without question, Wilson Sonsini has the experience, insight, and connections to assist animal health companies and investors. At a glance, our most relevant practice areas and services include:

Intellectual Property

  • Patent portfolio management
  • Preparation and prosecution of patent applications
  • Freedom-to-operate analysis
  • IP due diligence
  • Licensing and regulatory submissions
  • IP strategy and development
  • Trademarks, advertising, and promotions

Corporate

  • Corporate governance
  • Venture capital financings
  • Creative corporate structures
  • Capital markets
  • Mergers and acquisitions

Regulatory

  • Compliance counseling on laws, regulations, and industry standards
  • Assessing product development and regulatory approval options
  • Crisis management (responding to audits and other FDA inquiries)
  • Advertising and promotional strategy and review

Technology Transactions

  • Commercial transactions, including collaborations, joint ventures, strategic alliances, and partnering arrangements
  • Manufacturing, supply, and distribution agreements

Why Wilson Sonsini Is the Right Firm for Animal Health and Veterinary Medicine Clients

There are several reasons why we are the right law firm for animal health and veterinary medicine clients. Wilson Sonsini offers comparative advantages to clients across the sector, such as:

  • In addition to having a comprehensive and recognized corporate practice, we are a premier legal services provider to venture-funded technology start-ups with strong ties to VC firms and financing institutions, as well as accelerators and incubators.
  • Many of Wilson Sonsini’s 180-plus patent attorneys and patent agents have Ph.D.s and other advanced degrees in veterinary science, biology, chemistry, biomedical sciences, and other relevant fields. Additionally, more than 130 Wilson Sonsini attorneys and patent agents have been admitted to practice before the USPTO, and our team includes several former USPTO executives and USPTO patent examiners.
  • We have a talented regulatory/FDA team that includes seasoned veterans accustomed to advising clients throughout the FDA application and approval process; counseling companies on product labeling, advertising, and marketing matters; and advising investors on due diligence-related issues.
  • Our West Coast, East Coast, Mountain West, and Texas offices are in or near strategic U.S. animal health markets.

For decades, dating back to the birth of the technology revolution—when Silicon Valley earned its name as base camp for the fearless and daring—Wilson Sonsini has been at the center of innovation. But like our clients, we did not stay idle. Since our inception, we have partnered with companies making novel discoveries and developing the newest technologies. Wilson Sonsini maintains a position of strength that enables it to work effectively, intuitively, and seamlessly with companies and investors across the animal health industry.

Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Client Highlights
Wilson Sonsini Advises Assort Health on $76 Million Series B
On September 30, 2025, Assort Health, a comprehensive patient experience platform powered by specialty-specific agentic AI, announced the close of a $76 million Series B financing round led by Lightspeed Venture Partners, with investments by Felicis, First Round Capital, Chemistry, A*, Liquid2, and Quiet. A Wilson Sonsini Goodrich & Rosati team led by Lang Liu, Alex Youssef, and Andrew Lu advised Assort Health on the transaction.
Alerts
Clarifying FDA and USDA Jurisdiction over Animal Biological Products
Key Takeaways
Client Highlights
Wilson Sonsini Advises Infiniti Medical on Employee Benefit and Employment Matters Related to Acquisition by Creative Science
On March 3, 2025, Creative Science, a CIMA Animal Health company, and a leader in veterinary medical solutions, announced the acquisition of Infiniti Medical and its subsidiary Orthomed UK, two globally recognized brands specializing in veterinary interventional radiology, cardiology, soft tissue surgery, and orthopedics. Wilson Sonsini Goodrich & Rosati advised Infiniti Medical on employee benefit and compensation and employment matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Featurespace on Merger with Visa
Wilson Sonsini is pleased to have represented Featurespace as the lead advisor in its recently completed acquisition by Visa. Featurespace is a developer of real-time AI payments protection technology that prevents and mitigates payments fraud and financial crime risks.
Client Highlights
Wilson Sonsini Advises Movet on $5 Million Series A
On October 10, 2024, Colombia-based Movet, a veterinary network, announced that it successfully completed a $5 million Series A financing. The round was led by Wivet. Wilson Sonsini Goodrich & Rosati advised Movet on the transaction.
View All
Insights
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Client Highlights
Wilson Sonsini Advises Assort Health on $76 Million Series B
On September 30, 2025, Assort Health, a comprehensive patient experience platform powered by specialty-specific agentic AI, announced the close of a $76 million Series B financing round led by Lightspeed Venture Partners, with investments by Felicis, First Round Capital, Chemistry, A*, Liquid2, and Quiet. A Wilson Sonsini Goodrich & Rosati team led by Lang Liu, Alex Youssef, and Andrew Lu advised Assort Health on the transaction.
Alerts
Clarifying FDA and USDA Jurisdiction over Animal Biological Products
Key Takeaways
Client Highlights
Wilson Sonsini Advises Infiniti Medical on Employee Benefit and Employment Matters Related to Acquisition by Creative Science
On March 3, 2025, Creative Science, a CIMA Animal Health company, and a leader in veterinary medical solutions, announced the acquisition of Infiniti Medical and its subsidiary Orthomed UK, two globally recognized brands specializing in veterinary interventional radiology, cardiology, soft tissue surgery, and orthopedics. Wilson Sonsini Goodrich & Rosati advised Infiniti Medical on employee benefit and compensation and employment matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Featurespace on Merger with Visa
Wilson Sonsini is pleased to have represented Featurespace as the lead advisor in its recently completed acquisition by Visa. Featurespace is a developer of real-time AI payments protection technology that prevents and mitigates payments fraud and financial crime risks.
Client Highlights
Wilson Sonsini Advises Movet on $5 Million Series A
On October 10, 2024, Colombia-based Movet, a veterinary network, announced that it successfully completed a $5 million Series A financing. The round was led by Wivet. Wilson Sonsini Goodrich & Rosati advised Movet on the transaction.
View All
Affiliated Programs
Springboard's 2024 Healthcare & Technology Demo Day Showcase
Wilson Sonsini is proud to sponsor Springboard’s Healthcare & Technology Innovation Program for Fall 2024. As part of this collaboration, Deborah Smith will co-host the 2024 Healthcare & Technology Accelerator Demo Day on January 14, 2025, during the JPM Conference in San Francisco.
Events
Affiliated Programs
Springboard's 2024 Healthcare & Technology Demo Day Showcase
Wilson Sonsini is proud to sponsor Springboard’s Healthcare & Technology Innovation Program for Fall 2024. As part of this collaboration, Deborah Smith will co-host the 2024 Healthcare & Technology Accelerator Demo Day on January 14, 2025, during the JPM Conference in San Francisco.
John M. Brust
Partner
Seattle
John counsels start-ups in a wide range of matters, from formation and VC to IPOs and M&A.
  • Corporate
View Profile
Wendy L. Devine
Partner
San Francisco
Wendy is the firm's patent practice group leader and she represents clients in patent litigation and IP-related matters.
  • Litigation
View Profile
Brent Fassett
Partner
Boulder
Brent Fassett is a corporate partner in the Boulder office of Wilson Sonsini Goodrich & Rosati, where he represents emerging growth companies and the investors that support them, focusing on the life sciences and medical technology industries. He specializes in venture capital financings, public and private merger and acquisition transactions, IPOs, licensing and commercial agreements, employee compensation plans, public company reporting and disclosure issues, and securities law compliance.
  • Corporate
View Profile
Michael C. Labriola
Partner
London
Michael Labriola is a partner with Wilson Sonsini Goodrich & Rosati, where he counsels public and private technology, life sciences, and emerging growth companies through all stages of their growth. Michael has particular experience with Wilson Sonsini’s clients across the U.S. East Coast and Europe. He has a particular focus on supporting companies that undertake transformative events, such as growth financings, IPOs, acquisitions, and exit sales. Michael counsels clients in matters ranging from formation and early-stage venture financing to listings of publicly traded securities on U.S. and foreign exchanges to seasoned public offerings and private and public company acquisitions. He also has considerable experience in counseling publicly held companies on disclosure matters, SEC compliance, Nasdaq and NYSE listing matters, and other securities laws issues. In addition, Michael frequently represents investment banks, venture capital funds, and private equity firms in a broad range of investment transactions.
  • Corporate
View Profile
Lou Lieto
Partner
Boston
Dr. Lieto focuses on patent law-related matters for clients in the life sciences industry.
  • Patents and Innovations
View Profile
Danielle Naftulin
Partner
Palo Alto
Danielle Naftulin is a partner in the Palo Alto office of Wilson Sonsini with over 25 years of experience advising emerging companies and venture capital investors on a broad range of corporate transactions. Her practice focuses on the representation of high-growth life sciences and technology companies and their investors in formation and financing matters, as well as mergers and acquisitions, recapitalizations, spinouts, and general corporate matters. She has also represented clients in connection with initial public offerings and other public financing and strategic transactions.

Prior to joining the firm, Danielle was a partner in the business department at Cooley LLP in Palo Alto. She is an active member of the National Venture Capital Association’s General Counsel Advisory Board and a regular speaker on emerging companies and venture capital for Practising Law Institute, various law schools, and other organizations.
  • Corporate
View Profile
Sara L. Patak
Partner
Boulder
Sara L. Patak is a partner in the Boulder office of Wilson Sonsini Goodrich & Rosati. Her practice focuses on patent prosecution and intellectual property counseling, serving clients in a wide range of technology fields, including the pharmaceutical and biotechnology industries.
  • Patents and Innovations
View Profile
Craig E. Sherman
Partner
Seattle
Craig represents companies, venture capital firms, and investment banks in private placements and public offerings. He also has M&A, technology licensing, and domestic and international joint venture experience.
  • Corporate
View Profile
Lori P. Westin
Partner
San Diego
Dr. Lorelei (Lori) Westin is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati. Before joining the firm, Lori served as a federal law clerk for the Honorable John A. Houston in the Southern District of California. She also was a patent agent at Howrey Simon Arnold & White. Prior to Howrey, Lori had extensive experience as a research scientist, serving as a senior research scientist in Advanced Technologies at Nanogen, Inc.; a research associate in the Regulatory Biology Laboratory at the Salk Institute; and a postdoctoral fellow in the Laboratory of Molecular Genetics, CMB, at the Karolinska Institute in Sweden. She is the primary author of numerous scientific and legal publications, and is an inventor on seven issued U.S. patents on microchip and DNA amplification technology.
  • Patents and Innovations
View Profile
Eva F. Yin
Partner
Seattle
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.
  • Regulatory
View Profile
View All
People
John M. Brust
Partner
Seattle
John counsels start-ups in a wide range of matters, from formation and VC to IPOs and M&A.
  • Corporate
View Profile
Wendy L. Devine
Partner
San Francisco
Wendy is the firm's patent practice group leader and she represents clients in patent litigation and IP-related matters.
  • Litigation
View Profile
Brent Fassett
Partner
Boulder
Brent Fassett is a corporate partner in the Boulder office of Wilson Sonsini Goodrich & Rosati, where he represents emerging growth companies and the investors that support them, focusing on the life sciences and medical technology industries. He specializes in venture capital financings, public and private merger and acquisition transactions, IPOs, licensing and commercial agreements, employee compensation plans, public company reporting and disclosure issues, and securities law compliance.
  • Corporate
View Profile
Michael C. Labriola
Partner
London
Michael Labriola is a partner with Wilson Sonsini Goodrich & Rosati, where he counsels public and private technology, life sciences, and emerging growth companies through all stages of their growth. Michael has particular experience with Wilson Sonsini’s clients across the U.S. East Coast and Europe. He has a particular focus on supporting companies that undertake transformative events, such as growth financings, IPOs, acquisitions, and exit sales. Michael counsels clients in matters ranging from formation and early-stage venture financing to listings of publicly traded securities on U.S. and foreign exchanges to seasoned public offerings and private and public company acquisitions. He also has considerable experience in counseling publicly held companies on disclosure matters, SEC compliance, Nasdaq and NYSE listing matters, and other securities laws issues. In addition, Michael frequently represents investment banks, venture capital funds, and private equity firms in a broad range of investment transactions.
  • Corporate
View Profile
Lou Lieto
Partner
Boston
Dr. Lieto focuses on patent law-related matters for clients in the life sciences industry.
  • Patents and Innovations
View Profile
Danielle Naftulin
Partner
Palo Alto
Danielle Naftulin is a partner in the Palo Alto office of Wilson Sonsini with over 25 years of experience advising emerging companies and venture capital investors on a broad range of corporate transactions. Her practice focuses on the representation of high-growth life sciences and technology companies and their investors in formation and financing matters, as well as mergers and acquisitions, recapitalizations, spinouts, and general corporate matters. She has also represented clients in connection with initial public offerings and other public financing and strategic transactions.

Prior to joining the firm, Danielle was a partner in the business department at Cooley LLP in Palo Alto. She is an active member of the National Venture Capital Association’s General Counsel Advisory Board and a regular speaker on emerging companies and venture capital for Practising Law Institute, various law schools, and other organizations.
  • Corporate
View Profile
Sara L. Patak
Partner
Boulder
Sara L. Patak is a partner in the Boulder office of Wilson Sonsini Goodrich & Rosati. Her practice focuses on patent prosecution and intellectual property counseling, serving clients in a wide range of technology fields, including the pharmaceutical and biotechnology industries.
  • Patents and Innovations
View Profile
Craig E. Sherman
Partner
Seattle
Craig represents companies, venture capital firms, and investment banks in private placements and public offerings. He also has M&A, technology licensing, and domestic and international joint venture experience.
  • Corporate
View Profile
Lori P. Westin
Partner
San Diego
Dr. Lorelei (Lori) Westin is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati. Before joining the firm, Lori served as a federal law clerk for the Honorable John A. Houston in the Southern District of California. She also was a patent agent at Howrey Simon Arnold & White. Prior to Howrey, Lori had extensive experience as a research scientist, serving as a senior research scientist in Advanced Technologies at Nanogen, Inc.; a research associate in the Regulatory Biology Laboratory at the Salk Institute; and a postdoctoral fellow in the Laboratory of Molecular Genetics, CMB, at the Karolinska Institute in Sweden. She is the primary author of numerous scientific and legal publications, and is an inventor on seven issued U.S. patents on microchip and DNA amplification technology.
  • Patents and Innovations
View Profile
Eva F. Yin
Partner
Seattle
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.
  • Regulatory
View Profile
View All
Related Practices
  • Corporate
  • FDA Regulatory, Healthcare, and Consumer Products
  • Patents and Innovations
Related Industries
  • Biotech
  • FoodTech and AgTech
  • Life Sciences
  • Medical Devices
Recent Insights
Newsletters
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.
Learn More
Client Highlights
Wilson Sonsini Advises Assort Health on $76 Million Series B
On September 30, 2025, Assort Health, a comprehensive patient experience platform powered by specialty-specific agentic AI, announced the close of a $76 million Series B financing round led by Lightspeed Venture Partners, with investments by Felicis, First Round Capital, Chemistry, A*, Liquid2, and Quiet. A Wilson Sonsini Goodrich & Rosati team led by Lang Liu, Alex Youssef, and Andrew Lu advised Assort Health on the transaction.
Learn More
View All
Recent Events
Affiliated Programs
Springboard's 2024 Healthcare & Technology Demo Day Showcase
Wilson Sonsini is proud to sponsor Springboard’s Healthcare & Technology Innovation Program for Fall 2024. As part of this collaboration, Deborah Smith will co-host the 2024 Healthcare & Technology Accelerator Demo Day on January 14, 2025, during the JPM Conference in San Francisco.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.